1 active not recruiting, 1 not yet recruiting, 1 recruiting. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow mitazalimab: new trials by email Literature Review of mitazalimab trials Research Report on mitazalimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers mFOLFOX regimen, Mitazalimab - Biliary Tract Cancer (BTC) | Phase 2 / Phase 3 | Not yet recruiting | UNICANCER | 160 | 2026-07-01 | 2026-02-27 |
| Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer Odetiglucan, Mitazalimab - Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | University of Pennsylvania | 100 | 2025-11-25 | 2026-06-10 |
| Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients CD40 agonist mitazalimab in combination with chemotherapy - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Alligator Bioscience AB | 94 | 2021-09-17 | 2025-10-08 |
Biliary Tract Neoplasms (1) · Pancreatic Neoplasms (1)
Alligator Bioscience AB (1) · UNICANCER (1) · University of Pennsylvania (1)
France (2) · Belgium (1) · Spain (1) · United States (1)
Jean-Luc van Laethem, Prof. MD (1)